View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 16, 2020

Bold Therapeutics, Uni of Ottawa to research anti-viral drug for Covid-19

By Allie Nawrat

Vancouver-based Bold Therapeutics is partnering with the University of Ottawa, Canada, to explore the potential efficacy of its anti-viral BOLD-100 against Covid-19.

This drug inhibits the stress-induced upregulation of GRP78, which has a role in host recognition, viral entry and viral replication.

Bold has been investigating this anti-viral in combination with chemotherapy and other oncology agents in gastrointestinal cancer; the company is focused on overcoming drug resistance in cancer.

University of Ottawa faculty professor of medicine and Canada Research molecular virology and intrinsic immunity chair Dr Marc-André Langlois noted: “We will be using our lentiviral-based infection system, derived from HIV, equipped with the SARS-CoV-2 (COVID-19) spike, to study the impact of BOLD-100 on viral entry.

“There is an urgent need for novel antiviral agents effective against COVID-19 and related pathogens, and we look forward to advancing our understanding of the role that GRP78 plays in viral entry.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy